PSMA PET/CT for tyrosine-kinase inhibitor monitoring in metastatic renal cell carcinoma

被引：10
|
作者：
Mittlmeier, L. M. [1 ,2 ]
Unterrainer, M. [2 ,3 ]
Todica, A. [2 ]
Cyran, C. C. [3 ]
Rodler, S. [1 ]
Bartenstein, P. [2 ]
Stief, C. G. [1 ]
Ilhan, H. [2 ]
Staehler, M. [1 ]
机构：
[1] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Urol, Munich, Germany
[2] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Nucl Med, Munich, Germany
[3] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Radiol, Munich, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2020年 / 47卷 / 09期
关键词：
D O I：
10.1007/s00259-019-04636-6
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
[No abstract available]
引用
收藏
页码：2216 / 2217
页数：2
相关论文
共 50 条
  • [41] Pazopanib: an orally administered multitargeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma
    Koc, Gokhan
    Wang, Xu
    Luo, Yi
    CANADIAN JOURNAL OF UROLOGY, 2011, 18 (06) : 5991 - 5997
  • [42] Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma
    Dong-Hoe Koo
    Inkeun Park
    Jin-Hee Ahn
    Dae-Ho Lee
    Dalsan You
    In-Gab Jeong
    Cheryn Song
    Bumsik Hong
    Jun Hyuk Hong
    Hanjong Ahn
    Jae-Lyun Lee
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 339 - 347
  • [43] Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy
    Buchler, Tomas
    Poprach, Alexandr
    TARGETED ONCOLOGY, 2024, 19 (02) : 175 - 180
  • [44] Changes of PSMA expression on [18F]PSMA1007 PET are not correlated with morphological changes in patients with metastatic renal cell cancer undergoing tyrosine kinase and checkpoint inhibitor treatment
    Kunte, Sophie
    Unterrainer, Lena
    Unterrainer, Marcus
    Holzgreve, Adrien
    Rodler, Severin
    Kunz, Wolfgang
    Stief, Christian
    Bartenstein, Peter
    Staehler, Michael
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [45] Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?
    Chiara Pozzessere
    Maria Bassanelli
    Anna Ceribelli
    Sazan Rasul
    Shuren Li
    John O. Prior
    Francesco Cicone
    Current Urology Reports, 2019, 20
  • [46] Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?
    Pozzessere, Chiara
    Bassanelli, Maria
    Ceribelli, Anna
    Rasul, Sazan
    Li, Shuren
    Prior, John O.
    Cicone, Francesco
    CURRENT UROLOGY REPORTS, 2019, 20 (11)
  • [47] Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT
    Steven P. Rowe
    Michael A. Gorin
    Hans J. Hammers
    M. Som Javadi
    Hazem Hawasli
    Zsolt Szabo
    Steve Y. Cho
    Martin G. Pomper
    Mohamad E. Allaf
    Annals of Nuclear Medicine, 2015, 29 : 877 - 882
  • [48] Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT
    Rowe, Steven P.
    Gorin, Michael A.
    Hammers, Hans J.
    Javadi, M. Som
    Hawasli, Hazem
    Szabo, Zsolt
    Cho, Steve Y.
    Pomper, Martin G.
    Allaf, Mohamad E.
    ANNALS OF NUCLEAR MEDICINE, 2015, 29 (10) : 877 - 882
  • [49] A Pilot Study on 68Ga-PSMA-11 PET/CT in Assessing Metastatic Clear Cell Renal Cell Carcinoma
    Xu, Qinfeng
    Zang, Shiming
    Shao, Guoqiang
    Wang, Feng
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [50] BLOOD PRESSURE CHANGE IN THE TYROSINE-KINASE INHIBITORS TREATMENT OF DIALYSIS PATIENTS WITH RENAL CELL CARCINOMA
    Nakai, Kentaro
    Fujii, Hideki
    Watanabe, Kentaro
    Watanabe, Shuhei
    Awata, Rie
    Kono, Keiji
    Yonekura, Yuriko
    Goto, Shunsuke
    Fujisawa, Masato
    Nishi, Shinichi
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
12345